New Products, Partnerships, Product Compatibility, and Financial Results - Research Report on LabCorp, Covance, Sanofi, Align Technology, and Rockwell Medical
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, November 11, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting America Laboratory Corp. of Holdings (NYSE: LH), Covance Inc. (NYSE: CVD), Sanofi (NYSE: SNY), Align Technology Inc. (NASDAQ: ALGN), and Rockwell Medical, Inc. (NASDAQ: RMTI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Laboratory Corp. of America Holdings Research Report
On November 6, 2013, Laboratory Corp. of America Holdings (LabCorp) announced the availability of a 4th generation HIV antigen/antibody combination assay and a new diagnostic algorithm that improves screening for HIV infection. According to the Company, the 4th generation HIV assays have the ability to detect both the HIV antibodies (IgG and IgM) and the HIV p24 antigen simultaneously prior to seroconversion and the new assay also enables detection of HIV seven days earlier in acutely infected individuals as compared with the 3rd generation assays. The Company informed that it's newly introduced diagnostic algorithm uses the 4th generation test as a first step, with a highly sensitive and specific immunoassay that is FDA approved to differentiate between HIV-1 and HIV-2 infections. LabCorp stated that the Clinical Laboratory Standards Institute (CLSI) and the New York State Department of Health have recommended the use of the enhanced algorithm for HIV screening, and the Centers for Disease Control and Prevention (CDC) has recently issued two positive evaluations of the new HIV diagnostic testing algorithm. The Full Research Report on Laboratory Corp. of America Holdings - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/c267_LH]
--
Covance Inc. Research Report
On November 5, 2013, Covance Inc. (Covance) and Pathoquest announced an exclusive agreement to collaborate in providing next-generation sequencing (NGS) based biosafety assessments. Covance informed that this NGS-based platform can detect and identify viral contaminants within biologic compounds, such as monoclonal antibodies or vaccines, throughout the entire lifecycle of the product. Raymond Kaiser, Ph.D. and Global Vice President of BioPharmaceutical Chemistry, Manufacturing and Control (CMC) Solutions for Covance commented, "This collaboration will provide Covance clients with a high-quality solution to the critical problem of viral contamination of biologics during development and in released product. As a cutting-edge company in the field of NGS-based virus identification, Pathoquest's capability dovetails perfectly with our CMC analytical solutions to provide our clients access to the latest technology and patients with safer medications." The Full Research Report on Covance Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/5691_CVD]
--
Sanofi Research Report
On October 29, 2013, Sanofi's vaccines division, Sanofi Pasteur, announced a partnership with Bill
& Melinda Gates Foundation to explore and develop new platforms and methods aimed at accelerating vaccine R&D, especially in areas of global health. According to the Company, the Vaccine Discovery Partnership is a newly created, formal mechanism though which the Gates Foundation can directly collaborate with Sanofi Pasteur and other vaccine-pharmaceutical companies across disease areas of interest. John Shiver, PhD, Senior Vice President of R&D for Sanofi Pasteur, said, "The MOU with the Gates Foundation facilitates our working together to de-risk novel concepts, technologies, platforms, and approaches of mutual interest. This program provides a mechanism to pursue R&D of new candidate vaccines for global health in the preclinical and clinical phases up to and including Phase IIa clinical trials." The Full Research Report on Sanofi - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/29ea_SNY]
--
Align Technology Inc. Research Report
On October 30, 2013, Align Technology Inc. (Align Technology) announced that its iTero Intraoral Scanner is now compatible with the E4D TCAD CAM chairside design and milling system of E4D Technologies. The Company stated that the new workflow allows iTero clinicians to expand their offering of digital services to include same-day crowns, bridges, inlays, onlays and veneers, creating more opportunities to establish full-scale milling installations for the benefit of the practice and the patient. Timothy A. Mack, Align Vice President, Business Development, commented, "Connecting the iTero system to E4D's milling system is more than just an added function -- it extends the utility of the iTero system to offer restorations in a single visit." He added, "iTero is the only scanner that offers certified connectivity with a milling system, a milled model service and of course, with Invisalign®." The Full Research Report on Align Technology Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/69b3_ALGN]
--
Rockwell Medical, Inc. Research Report
On November 5, 2013, Rockwell Medical, Inc. (Rockwell) released its Q3 2013 financial results with sales of $13.1 million representing an increase of 3.2% YoY. The Company posted net loss of $13.2 million or $0.34 per diluted share compared to $17.9 million or $0.86 per diluted share in Q3 2012. Rob Chioini, Founder, Chairman and CEO of Rockwell stated, "During the third quarter we achieved several major clinical milestones that have the potential to transform Rockwell. Top line data from our Phase 3 CRUISE-2 study was exceptional, confirming the prior CRUISE-1 results with an identical p-value and exhibiting an excellent safety profile." He added, "We look forward to receiving FDA manufacturing approval for Calcitriol, which will enable us to offer the lowest cost active vitamin D injection to dialysis clinics across the U.S., who are actively seeking low-cost drug alternatives." The Full Research Report on Rockwell Medical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/3079_RMTI]
----
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
AnalystsCorner.com
Share this article